前瞻性外部验证IOTA方法分类附件肿块及回顾性评估两步策略(良性描述符与ADNEX模型)的葡萄牙多中心研究
该前瞻性多中心诊断准确性研究纳入2016年1月至2021年12月在葡萄牙里斯本三家三级转诊中心因至少一个附件肿瘤接受手术的连续患者571例,以组织病理学为参考标准,验证IOTA简单规则、LR2和ADNEX模型并与主观评估及RMI比较,同时回顾性验证MBDs联合ADNEX的两步策略。结果显示IOTA方法表现良好至优秀,优于RMI;ADNEX模型准确性最高但区分恶性亚型的能力受样本量限制;MBDs可可靠识别良性疾病,两步策略适合日常临床实践。
要点
- IOTA SRs在80.0%患者中适用,敏感度94.8%、特异度98.6%,表现优秀。
- ADNEX模型(含CA 125)AUC 0.962,准确性优于RMI(AUC 0.913)。
- MBDs适用于26.3%(150/571)病例且均为良性,两步策略可避免对所有患者计算恶性风险。
核心结论
- IOTA方法在葡萄牙人群中表现良好至优秀,优于RMI。
- ADNEX模型在准确性上优于其他方法,但其区分恶性亚型的能力解读受样本量和肿瘤亚型患病率差异大的限制。
- IOTA MBDs可可靠识别良性疾病。
- 由MBDs适用时直接判定良性、不适用时再应用ADNEX模型组成的两步策略适合日常临床实践,可避免对所有患者计算恶性风险。
研究设计与样本
- 前瞻性多中心诊断准确性研究,2016年1月至2021年12月在葡萄牙里斯本三家三级转诊中心纳入连续患者571例。
- 纳入标准为超声诊断至少一个附件肿瘤并接受手术者;由具有IOTA认证的II级或III级超声医师完成所有超声评估。
- 参考标准为组织病理学诊断;从医院数据库收集患者临床数据和血清CA 125水平。
- 以主观评估、RMI、IOTA SRs、LR2和ADNEX模型(含与不含CA 125)对每个附件肿块进行良恶性分类。
- 第二阶段回顾性采用两步策略(MBDs + ADNEX)对所有附件肿瘤进行分类。
诊断标准与关键数值
- 主观评估鉴别良恶性的总体敏感度97.9%、特异度83.6%。
- RMI特异度高(95.6%)但敏感度很低(58.7%),AUC为0.913。
- IOTA SRs在80.0%患者中适用,敏感度94.8%、特异度98.6%。
- LR2在恶性风险截断值10%时敏感度84.6%、特异度86.9%、AUC 0.939。
- ADNEX模型在截断值10%时,含CA 125与不含CA 125的敏感度分别为95.8%与98.6%、特异度分别为82.5%与79.7%、AUC分别为0.962与0.960。
临床应用与阅片要点
- ADNEX模型区分良性肿块与原发性浸润性附件癌II-IV期时AUC最高(0.991),区分原发性浸润性附件癌I期与附件转移灶时AUC最低(0.696)。
- ADNEX模型校准图提示其较观察到的恶性比例低估风险。
- 作者认为MBDs可可靠识别良性疾病,两步策略适合日常临床实践。
局限性
- ADNEX模型区分恶性亚型的能力解读受样本量和肿瘤亚型患病率差异大的限制。
- ADNEX模型校准图提示其较观察到的恶性比例低估风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To externally and prospectively validate the International Ovarian Tumor Analysis (IOTA) Simple Rules (SRs), Logistic Regression model 2 (LR2) and Assessment of Different NEoplasias in the adneXa (ADNEX) model in a Portuguese population, comparing these approaches with subjective assessment and the risk-of-malignancy index (RMI), as well as with each other. This study also aimed to retrospectively validate the IOTA two-step strategy, using modified benign simple descriptors (MBDs) followed by the ADNEX model in cases in which MBDs were not applicable.
METHODS: This was a prospective multicenter diagnostic accuracy study conducted between January 2016 and December 2021 of consecutive patients with an ultrasound diagnosis of at least one adnexal tumor, who underwent surgery at one of three tertiary referral centers in Lisbon, Portugal. All ultrasound assessments were performed by Level-II or -III sonologists with IOTA certification. Patient clinical data and serum CA 125 levels were collected from hospital databases. Each adnexal mass was classified as benign or malignant using subjective assessment, RMI, IOTA SRs, LR2 and the ADNEX model (with and without CA 125). The reference standard was histopathological diagnosis. In the second phase, all adnexal tumors were classified retrospectively using the two-step strategy (MBDs + ADNEX). Sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios and overall accuracy were determined for all methods. Receiver-operating-characteristics curves were constructed and corresponding areas under the curve (AUC) were determined for RMI, LR2, the ADNEX model and the two-step strategy. The ADNEX model calibration plots were constructed using locally estimated scatterplot smoothing (LOESS).
RESULTS: Of the 571 patients included in the study, 428 had benign disease and 143 had malignant disease (prevalence of malignancy, 25.0%), of which 42 had borderline ovarian tumor, 93 had primary invasive adnexal cancer and eight had metastatic tumors in the adnexa. Subjective assessment had an overall sensitivity of 97.9% and a specificity of 83.6% for distinguishing between benign and malignant lesions. RMI showed high specificity (95.6%) but very low sensitivity (58.7%), with an AUC of 0.913. The IOTA SRs were applicable in 80.0% of patients, with a sensitivity of 94.8% and specificity of 98.6%. The IOTA LR2 had a sensitivity of 84.6%, specificity of 86.9% and an AUC of 0.939, at a malignancy risk cut-off of 10%. At the same cut-off, the sensitivity, specificity and AUC for the ADNEX model with vs without CA 125 were 95.8% vs 98.6%, 82.5% vs 79.7% and 0.962 vs 0.960, respectively. The ADNEX model gave heterogeneous results for distinguishing between benign masses and different subtypes of malignancy, with the highest AUC (0.991) for discriminating benign masses from primary invasive adnexal cancer Stages II-IV, and the lowest AUC (0.696) for discriminating primary invasive adnexal cancer Stage I from metastatic lesion in the adnexa. The calibration plot suggested underestimation of the risk by the ADNEX model compared with the observed proportion of malignancy. The MBDs were applicable in 26.3% (150/571) of cases, of which none was malignant. The two-step strategy using the ADNEX model in the second step only, with and without CA 125, had AUCs of 0.964 and 0.961, respectively, which was similar to applying the ADNEX model in all patients.
CONCLUSIONS: The IOTA methods showed good-to-excellent performance in the Portuguese population, outperforming RMI. The ADNEX model was superior to other methods in terms of accuracy, but interpretation of its ability to distinguish between malignant subtypes was limited by sample size and large differences in the prevalence of tumor subtypes. The IOTA MBDs are reliable in identifying benign disease. The two-step strategy comprising application of MBDs followed by the ADNEX model if MBDs are not applicable, is suitable for daily clinical practice, circumventing the need to calculate the risk of malignancy in all patients. © 2024 International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Borges AL, Brito M, Ambrósio P, et al. Prospective external validation of IOTA methods for classifying adnexal masses and retrospective assessment of two-step strategy using benign descriptors and ADNEX model: Portuguese multicenter study. Ultrasound Obstet Gynecol. 2024. PMID: 38477149. doi:10.1002/uog.27641
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。